Formulary Exclusions & Non-FDA Compounded Medications
Formulary Exclusions & Non-FDA Compounded Medications
(especially Low Dose Naltrexone and off-label use)
1. What “Formulary Exclusion” Means
A formulary is your insurance plan’s official list of covered medications.
If a medication is excluded, it means the insurer has chosen not to cover it under any circumstances — even with a prior authorization or appeal, unless a medical exception is granted.
Common Reasons for Exclusion
-
Cost containment: insurer has preferred “tiered” alternatives
-
Non-FDA approval: the medication or compounded formulation lacks FDA approval
-
Off-label use: prescribed for a condition not listed on the FDA label
-
Bulk powder compounding: the active ingredient is sourced in raw form rather than from a manufactured FDA-approved product
🔍 Example: Compounded Low Dose Naltrexone (LDN) is excluded from most Medicare Part D formularies because it’s not an FDA-approved finished drug and is considered “experimental or unproven” for many conditions — despite extensive clinical evidence supporting its off-label use.
2. Understanding Compounded & Non-FDA Medications
Compounded Medications
Compounding is when a pharmacist creates a medication tailored to the patient — adjusting the dose, removing allergens, or combining ingredients.
Why they’re often denied:
-
Not FDA-approved as a “finished” drug product
-
May be made using “bulk” (raw) powders not approved for that use
-
Insurers claim safety/efficacy cannot be guaranteed without FDA oversight
However, Medicare and private insurers can cover compounded drugs if:
-
Every active ingredient is part of an FDA-approved drug,
-
The compounded formula is “reasonable and necessary” for treatment,
-
It’s prescribed by a licensed provider and dispensed by a licensed pharmacy.
3. Off-Label Use & Why It Matters
Off-label use means a medication is prescribed for a condition or at a dosage not specifically listed on its FDA-approved labeling.
This practice is common and legal — the FDA regulates manufacturers, not physicians.
Insurers’ stance:
They often deny coverage for off-label uses unless:
-
Supported by recognized compendia (e.g., DrugDex, AHFS, NCCN), or
-
Backed by peer-reviewed medical evidence showing effectiveness for the diagnosed condition.
⚖️ Example: LDN (1.5 – 4.5 mg) is off-label because the FDA-approved form of naltrexone (50 mg) is for opioid/alcohol dependence — but off-label low-dose use is well-documented for autoimmune and inflammatory disorders.
4. How to Challenge Formulary & Compounding Denials
Step 1 – Request a Coverage Determination
Ask your plan in writing to reconsider coverage for the compounded or excluded medication.
Include:
-
Provider’s Letter of Medical Necessity
-
Supporting peer-reviewed studies
-
Explanation of why FDA-approved alternatives are not appropriate
Step 2 – File a Level 1 Appeal
If denied, submit an appeal citing:
-
Your plan’s obligation under CMS § 423.578 (Part D exception requests)
-
Supporting evidence from clinical literature
-
Any prior success or improvement with the medication
Step 3 – Escalate to Independent Review
Under Medicare Part D:
-
Level 1 → Redetermination by plan
-
Level 2 → Reconsideration by an Independent Review Entity (IRE)
-
Level 3 → Administrative Law Judge (ALJ) hearing (if over $180 in dispute)
🧾 AKG Advocacy Tip: Keep copies of every page — denials, evidence, provider statements, research articles — and label them clearly for your record or appeal packet.
5. Key Evidence to Include in Your Appeal
✅ Physician’s detailed Letter of Medical Necessity (diagnoses, dosage, treatment history)
✅ Published peer-reviewed studies supporting the off-label use
✅ Documentation of failure or intolerance to formulary alternatives
✅ Pharmacy compounding log or verification of ingredient source (if available)
✅ Patient statement describing impact and improvement
6. Example Denial Reason vs. Rebuttal
| Denial Reason | How to Respond |
|---|---|
| “Medication not FDA-approved.” | Clarify that compounding from approved ingredients is permitted under 21 U.S.C. § 353a and is widely accepted in clinical practice. |
| “Use is experimental or investigational.” | Cite peer-reviewed studies and recognized compendia demonstrating efficacy. |
| “Medication not on formulary.” | Request a formulary exception under CMS guidelines citing lack of effective alternatives. |
| “Bulk ingredient not covered.” | Provide evidence that compounded LDN uses pure naltrexone hydrochloride identical to FDA-approved product, only in adjusted dosage. |
7. Real-World Example: Low Dose Naltrexone (LDN)
| Issue | Insurer Argument | How to Counter |
|---|---|---|
| Non-FDA-approved | “LDN not an FDA-approved finished product.” | Compounding from an FDA-approved ingredient is permitted; physician supervision ensures safety. |
| Off-label use | “Not FDA-approved for autoimmune disease.” | Cite studies on LDN’s immune-modulating and anti-inflammatory effects (e.g., Younger et al., Pain Med 2013). |
| Formulary exclusion | “Excluded medication category.” | File an exception request demonstrating no alternative provides equivalent benefit or tolerance. |
Comments
Post a Comment